Hence, several recent studies have also investigated the effects of genetic and pharmacological inhibition of myostatin, and the resultant resistance-trained phenotype, on the prevention and treatment of obesity and type 2 diabetes mellitus [112, 113]. The gene discussed is MSTN; the disease is obesity due to melanocortin 4 receptor deficiency.